• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性淋巴细胞白血病中TP53改变的图谱:数据挖掘突变数据库

Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia Data Mining Mutation Databases.

作者信息

Soussi Thierry, Baliakas Panagiotis

机构信息

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Sorbonne Université, UPMC Univ Paris 06, Paris, France.

出版信息

Front Oncol. 2022 Feb 16;12:808886. doi: 10.3389/fonc.2022.808886. eCollection 2022.

DOI:10.3389/fonc.2022.808886
PMID:35251978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8890000/
Abstract

Locus-specific databases are invaluable tools for both basic and clinical research. The extensive information they contain is gathered from the literature and manually curated by experts. Cancer genome sequencing projects generate an immense amount of data, which are stored directly in large repositories (cancer genome databases). The presence of a defect (17p deletion and/or mutations) is an independent prognostic factor in chronic lymphocytic leukemia (CLL) and status analysis has been adopted in routine clinical practice. For that reason, mutation databases have become essential for the validation of the plethora of variants detected in tumor samples. profiles in CLL are characterized by a great number of subclonal mutations with low variant allelic frequencies and the presence of multiple minor subclones harboring different mutations. In this review, we describe the various characteristics of the multiple levels of heterogeneity of variants in CLL through the analysis of mutation databases and the utility of their diagnosis in the clinic.

摘要

基因座特异性数据库对于基础研究和临床研究而言都是非常宝贵的工具。它们所包含的大量信息是从文献中收集并由专家人工整理的。癌症基因组测序项目产生了海量数据,这些数据直接存储在大型数据库(癌症基因组数据库)中。缺陷(17p缺失和/或突变)的存在是慢性淋巴细胞白血病(CLL)的一个独立预后因素,并且该状态分析已被应用于常规临床实践中。因此,突变数据库对于验证在肿瘤样本中检测到的大量变异至关重要。CLL中的突变谱具有大量低变异等位基因频率的亚克隆突变以及存在多个携带不同突变的小亚克隆的特征。在这篇综述中,我们通过分析突变数据库描述了CLL中变异多水平异质性的各种特征及其在临床诊断中的效用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59ee/8890000/549da6a8b9ce/fonc-12-808886-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59ee/8890000/824fab5e4815/fonc-12-808886-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59ee/8890000/02f92a35718f/fonc-12-808886-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59ee/8890000/5442f91d3b18/fonc-12-808886-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59ee/8890000/549da6a8b9ce/fonc-12-808886-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59ee/8890000/824fab5e4815/fonc-12-808886-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59ee/8890000/02f92a35718f/fonc-12-808886-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59ee/8890000/5442f91d3b18/fonc-12-808886-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59ee/8890000/549da6a8b9ce/fonc-12-808886-g004.jpg

相似文献

1
Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia Data Mining Mutation Databases.慢性淋巴细胞白血病中TP53改变的图谱:数据挖掘突变数据库
Front Oncol. 2022 Feb 16;12:808886. doi: 10.3389/fonc.2022.808886. eCollection 2022.
2
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study.慢性淋巴细胞白血病中亚克隆 TP53 突变的频谱:一项下一代测序回顾性研究。
Hematol Oncol. 2022 Dec;40(5):962-975. doi: 10.1002/hon.3063. Epub 2022 Aug 18.
3
Deep targeted sequencing of in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment.慢性淋巴细胞白血病中 的深度靶向测序:诊断时和治疗时的临床影响。
Haematologica. 2019 Apr;104(4):789-796. doi: 10.3324/haematol.2018.195818. Epub 2018 Dec 4.
4
TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.临床实践中的TP53突变分析:来自慢性淋巴细胞白血病的经验教训
Hum Mutat. 2014 Jun;35(6):663-71. doi: 10.1002/humu.22508. Epub 2014 Feb 5.
5
Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.CLL 中的预后和治疗分层:关注 17p 缺失和 p53 突变。
Ann Hematol. 2018 Dec;97(12):2269-2278. doi: 10.1007/s00277-018-3503-6. Epub 2018 Oct 12.
6
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.TP53突变在慢性淋巴细胞白血病中的预后价值独立于17p13缺失:对总生存期和化疗难治性的影响
Clin Cancer Res. 2009 Feb 1;15(3):995-1004. doi: 10.1158/1078-0432.CCR-08-1630.
7
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.氟达拉滨难治性慢性淋巴细胞白血病(CLL)中p53通路缺陷的详细分析:在前瞻性临床试验中剖析17p缺失、TP53突变、p53-p21功能障碍和miR34a的作用
Blood. 2009 Sep 24;114(13):2589-97. doi: 10.1182/blood-2009-05-224071. Epub 2009 Jul 30.
8
The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.17p 缺失细胞的百分比和 17p 缺失亚克隆的大小在慢性淋巴细胞白血病中具有预后意义。
Genes Chromosomes Cancer. 2019 Jan;58(1):43-51. doi: 10.1002/gcc.22692. Epub 2018 Nov 29.
9
TP53 mutation and survival in chronic lymphocytic leukemia.TP53 突变与慢性淋巴细胞白血病的生存。
J Clin Oncol. 2010 Oct 10;28(29):4473-9. doi: 10.1200/JCO.2009.27.8762. Epub 2010 Aug 9.
10
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.单等位基因TP53失活与慢性淋巴细胞白血病的不良预后相关:长期随访的详细基因特征分析结果
Blood. 2008 Oct 15;112(8):3322-9. doi: 10.1182/blood-2008-04-154070. Epub 2008 Aug 8.

引用本文的文献

1
The TP53 tumor suppressor gene: From molecular biology to clinical investigations.TP53肿瘤抑制基因:从分子生物学到临床研究
J Intern Med. 2025 Aug;298(2):78-96. doi: 10.1111/joim.20106. Epub 2025 Jun 16.
2
The Broad Spectrum of Mutations in CLL: Evidence of Multiclonality and Novel Mutation Hotspots.慢性淋巴细胞白血病中广泛的突变谱:多克隆性及新突变热点的证据
Hum Mutat. 2023 May 9;2023:4880113. doi: 10.1155/2023/4880113. eCollection 2023.
3
Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment.

本文引用的文献

1
Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia.低变异等位基因频率的突变预示慢性淋巴细胞白血病患者生存期短。
Clin Cancer Res. 2021 Oct 15;27(20):5566-5575. doi: 10.1158/1078-0432.CCR-21-0701. Epub 2021 Jul 20.
2
The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.慢性淋巴细胞白血病的持续未满足需求:TP53 破坏、Richter 转化及其他。
Hematol Oncol Clin North Am. 2021 Aug;35(4):739-759. doi: 10.1016/j.hoc.2021.04.001. Epub 2021 May 28.
3
Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene.
慢性淋巴细胞白血病分子生物学的最新进展:如何定义预后并指导治疗
Cancers (Basel). 2024 Oct 14;16(20):3483. doi: 10.3390/cancers16203483.
4
Cancer associated variant enrichment CAVE, a gene agnostic approach to identify low burden variants in chronic lymphocytic leukemia.癌症相关变异富集(CAVE),一种鉴定慢性淋巴细胞白血病中低负担变异的基因不可知方法。
Sci Rep. 2024 Sep 20;14(1):21962. doi: 10.1038/s41598-024-73027-1.
5
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.ERIC 建议对慢性淋巴细胞白血病中的 TP53 基因突变进行分析-2024 更新。
Leukemia. 2024 Jul;38(7):1455-1468. doi: 10.1038/s41375-024-02267-x. Epub 2024 May 16.
6
Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants.慢性淋巴细胞白血病中p53信号通路的遗传变异性分析。TP53、MDM2和NQO1基因变异的个体及联合分析。
Ann Hematol. 2024 Dec;103(12):5703-5712. doi: 10.1007/s00277-024-05794-w. Epub 2024 May 14.
7
Disease-controlled multiple myeloma in a patient with 17p gain and t(4;14): A case report.一名伴有17p获得和t(4;14)的疾病控制的多发性骨髓瘤患者:病例报告
Heliyon. 2024 Apr 2;10(7):e28950. doi: 10.1016/j.heliyon.2024.e28950. eCollection 2024 Apr 15.
8
Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.低负担的 TP53 突变是 CLL 中常见的遗传事件,增加了治疗起始的风险。
J Pathol Clin Res. 2024 Jan;10(1):e351. doi: 10.1002/cjp2.351. Epub 2023 Nov 21.
9
Copy Number Variations and Gene Mutations Identified by Multiplex Ligation-Dependent Probe Amplification in Romanian Chronic Lymphocytic Leukemia Patients.通过多重连接依赖探针扩增技术在罗马尼亚慢性淋巴细胞白血病患者中鉴定出的拷贝数变异和基因突变
J Pers Med. 2023 Aug 9;13(8):1239. doi: 10.3390/jpm13081239.
10
Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting.在临床环境中,5%的变异等位基因频率是慢性淋巴细胞白血病中通过下一代测序检测到的变异的可靠报告阈值。
Hemasphere. 2022 Aug 2;6(8):e761. doi: 10.1097/HS9.0000000000000761. eCollection 2022 Aug.
鉴定和功能表征 TP53 基因编码区的新型错义单核苷酸多态性。
Cell Death Differ. 2021 May;28(5):1477-1492. doi: 10.1038/s41418-020-00672-0. Epub 2020 Nov 30.
4
Comprehensive assessment of TP53 loss of function using multiple combinatorial mutagenesis libraries.利用多个组合诱变文库对 TP53 功能丧失进行综合评估。
Sci Rep. 2020 Nov 23;10(1):20368. doi: 10.1038/s41598-020-74892-2.
5
Treatment of Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病的治疗
N Engl J Med. 2020 Jul 30;383(5):460-473. doi: 10.1056/NEJMra1908213.
6
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.伊布替尼治疗一线和复发/难治性慢性淋巴细胞白血病:关键性 Ib/II 期 PCYC-1102 研究的最终分析。
Clin Cancer Res. 2020 Aug 1;26(15):3918-3927. doi: 10.1158/1078-0432.CCR-19-2856. Epub 2020 Mar 24.
7
Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.TP53、BIRC3、ATM 和 MAPK-ERK 基因在慢性淋巴细胞白血病中的临床意义:来自 UK LRF CLL4 试验的随机数据。
Leukemia. 2020 Jul;34(7):1760-1774. doi: 10.1038/s41375-020-0723-2. Epub 2020 Feb 3.
8
Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study.基因组阵列识别具有基因组复杂性的高危慢性淋巴细胞白血病:一项多中心研究。
Haematologica. 2021 Jan 1;106(1):87-97. doi: 10.3324/haematol.2019.239947.
9
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.癌症基因组图谱中 TP53 基因与通路改变的综合分析。
Cell Rep. 2019 Jul 30;28(5):1370-1384.e5. doi: 10.1016/j.celrep.2019.07.001.
10
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.维奈托克联合奥滨尤妥珠单抗治疗伴有合并症的 CLL 患者
N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.